{"id":138,"date":"2019-01-14T13:29:32","date_gmt":"2019-01-14T13:29:32","guid":{"rendered":"https:\/\/primaderma.ro\/2019\/?page_id=138"},"modified":"2019-04-08T14:03:34","modified_gmt":"2019-04-08T14:03:34","slug":"sponsori","status":"publish","type":"page","link":"https:\/\/pdi.ro\/2019\/sponsori\/","title":{"rendered":"Parteneri"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”on|off|off” _builder_version=”3.19.4″ custom_margin=”||” custom_padding=”15px||29px” top_divider_style=”waves2″ top_divider_color=”#f0622a” top_divider_flip=”horizontal|vertical” bottom_divider_style=”waves2″ bottom_divider_color=”#fcdedb” bottom_divider_height=”105px” bottom_divider_flip=”vertical” collapsed=”off”][et_pb_fullwidth_header title=”{%22dynamic%22:true,%22content%22:%22post_title%22,%22settings%22:{%22before%22:%22%22,%22after%22:%22%22}}” text_orientation=”right” header_image_url=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/Primaderma2019_logo_300px.png” disabled_on=”on|on|off” _builder_version=”3.19.4″ _dynamic_attributes=”title” title_font=”Kaushan Script||||||||” title_text_align=”right” title_text_color=”#f0622a” title_font_size=”50px” content_font=”|600||on|||||” content_text_align=”center” content_text_color=”#686766″ content_font_size=”15px” content_font_size_phone=”15px” content_font_size_last_edited=”on|desktop” subhead_font=”||||||||” background_color=”rgba(239,145,107,0.54)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back.jpg” background_layout=”light” custom_margin=”0px||8px” custom_padding=”40px||40px||true”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ top_divider_style=”waves2″ top_divider_color=”#fcdedb” top_divider_height=”95px” top_divider_flip=”horizontal|vertical”][et_pb_row _builder_version=”3.19.4″][et_pb_column type=”4_4″ _builder_version=”3.19.4″][et_pb_text disabled_on=”on|on|on” _builder_version=”3.19.18″ disabled=”on”]<\/p>\n

Dac\u0103 firma pe care o reprezenta\u0163i dore\u015fte s\u0103-\u015fi promoveze produsele \u015fi serviciile \u00een cadrul PDI 2019, at\u00e2t \u00een timpul evenimentului, c\u00e2t \u015fi \u00een toat\u0103 perioada de organizare premerg\u0103toare acestuia, v\u0103 rug\u0103m s\u0103 ne contacta\u0163i.<\/p>\n

At\u00e2t organizatorii, c\u00e2t \u015fi operatorul evenimentului, Eventer.Net, v\u0103 stau la dispozi\u0163ie pentru orice informa\u0163ii \u00een plus sau clarific\u0103ri ve\u0163i avea nevoie. Pentru informa\u0163ii despre pachetele de servicii de promovare v\u0103 rug\u0103m s\u0103 ne contacta\u0163i prin e-mail la adresa contact@pdi.ro\/2019.<\/a>\u00a0sau telefonic la 0332.40.88.05.<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Comitetul de organizare a\u00a0<\/span>Prim\u0103verii Dermatologice Ie\u015fene 2019 dore\u015fte s\u0103 mul\u0163umeasc\u0103 urm\u0103torilor parteneri din industria farmaceutic\u0103 pentru sprijinul acordat \u00een organizarea evenimentului:<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/sponsori_1.png” _builder_version=”3.19.18″][\/et_pb_image][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/sponsori_2.png” _builder_version=”3.19.18″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″ text_font=”||||||||”]<\/p>\n

Sesiuni \u015ftiin\u0163ifice cu sus\u0163inerea partenerilor din industria farmaceutic\u0103<\/strong><\/span><\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/Servier-sigla.png” align=”center” _builder_version=”3.19.18″ max_width=”23%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Bucuria fiec\u0103rui pas!<\/span>
Speakeri: Prof. Dr. Andrew Nicolaide, Prof. Dr. Daciana Br\u0103ni\u015fteanu<\/span><\/p>\n

Senza\u021bia de picioare grele, aflat\u0103 la limita dintre simptom si percep\u021bie, afecteaz\u0103 calitatea vie\u021bii multora dintre rom\u00e2ni. De multe ori ignorat\u0103 sau trecut\u0103 cu vederea, aceast\u0103 situa\u021bie neplacut\u0103 vizeaz\u0103 30.5% din popula\u021bia ce se adreseaz\u0103 medicului de familie*. \u00cen urma chestion\u0103rii, aproape 1 din 3 persoane ce intrau \u00een cabinet aveau acest disconfort, f\u0103r\u0103 s\u0103 se poat\u0103 formula un diagnostic ce ar incrimina vreo patologie venoas\u0103.
\u00cen lupta cu disconfortul, persoanele afectate \u00eencearc\u0103 multiple solu\u021bii. Dintre acestea, peste 50% apeleaz\u0103 la un topic pentru hidratare, energizare, r\u0103corire*. \u00cens\u0103, multe dintre aceste solu\u021bii nu reu\u0219esc s\u0103 aduc\u0103 r\u0103spunsul la nevoile utilizatorilor.
Servier a colaborat cu cei mai renumi\u021bi exper\u021bi \u00een cosmeticele de lux franceze, pentru a dezvolta noua crem\u0103 energizant\u0103 pentru picioare, Cedraflon. Acest concept care combin\u0103 \u0219tiin\u021ba (expertiza Servier \u00een domeniul flebologiei) cu luxul (know-how-ul din spatele marilor branduri cosmetice), ofer\u0103 un r\u0103spuns pentru eliberarea senza\u021biei de picioare grele, aduc\u00e2nd \u0219i beneficii adi\u021bionale: hidratare, tonifiere.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/AbbVie-logo.png” align=”center” _builder_version=”3.19.18″ max_width=”27%” custom_margin=”||28px”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″ custom_margin=”-51px||”]<\/p>\n

Este psoriazisul un puzzle greu de rezolvat?<\/span>
Speakeri: Daciana Branisteanu, Andra Balanescu, Robert Ancuceanu<\/span><\/p>\n

Obiectivul comunicarii este de a facilita accesul medicilor dermatologi la informatii medicale de actualitate privind comorbiditatile si bolile asociate din psoriazis, contribuind astfel la optimizarea managementului pacientului cu aceasta afectiune. Simpozionul va aborda tema managementului interdisciplinar al pacientului cu psoriazis si afectare articulara. O alta tema abordata se refera la utilitatea pe care o confera flexibilitatea dozelor corelata cu nevoile specifice ale persoanelor afectate de psoriazis.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/image001.png” align=”center” _builder_version=”3.19.18″][\/et_pb_image][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Terapiile biologice: date globale din studiile clinice si registrele de pacienti; focus pe ustekinumab<\/span>
Speaker: D. Branisteanu<\/span><\/p>\n

Ghidul pentru terapii biologice in psoriazis al Asociatiei Britanice a Dermatologilor, recent actualizat, recomanda adalimumab si ustekinumab ca terapii biologice de prima linie (impreuna cu secukinumab) iar etanercept ca terapie biologica de a doua linie (Smith \u0219i colab., 2017). Aceast\u0103 decizie se bazeaza \u00een principal pe dovezi privind eficacitatea din studiile clinice (Jabbar-Lopez et al., 2017).
Tratamentul cu ustekinumab la fiecare 12 s\u0103pt\u0103m\u00e2ni are eficacitate pentru majoritatea pacien\u021bilor cu psoriazis moderat p\u00e2n\u0103 la sever (PHOENIX 2). Tratamentul continuu 5 ani cu ustekinumab a determinat un r\u0103spuns clinic stabil \u0219i a ar\u0103tat un profil de siguran\u021b\u0103 consistent cu studiile anterioare (PHOENIX 1)
Lipsa eficacit\u0103\u021bii a fost motivul cel mai frecvent pentru \u00eentreruperea tratamentului biologic. Supravie\u021buirea a fost superioar\u0103 pentru ustekinumab comparativ cu infliximab, adalimumab \u0219i etanercept la pacien\u021bii cu psoriazis. (PSOLAR)
Nu exist\u0103 cre\u0219teri semnificative statistic ale riscului de infec\u021bii grave pentru oricare dintre terapiile biologice comparativ cu terapiile sistemice non-biologice la pacien\u021bii cu psoriazis (BADBIR)
Terapiile biologice sunt asociate cu o rat\u0103 mai sc\u0103zut\u0103 de reac\u0163ii adverse asociate cu \u00eentreruperea tratamentului comparativ cu terapiile clasice, \u00een practica clinic\u0103 real\u0103, iar dintre acestea, ustekinumab a prezentat cea mai mic\u0103 inciden\u021b\u0103. (Proiectul Biobadaderm)
Atributele pe care majoritatea pacien\u021bilor le-au indicat ca fiind cele mai importante sau relevante \u00een ce prive\u015fte preferin\u0163a pentru regimul terapeutic au inclus riscul de reac\u0163ii adverse, durata r\u0103spunsului la terapie, modul \u0219i frecven\u021ba administr\u0103rii. (Protimisis, 2017).<\/p>\n

De la date globale la practica locala, focus pe ustekinumab: studii de caz<\/span>
Speaker: C. Curea<\/span><\/p>\n

Psoriazisul are un impact negativ important asupra calitatii vie\u021bii pacien\u021bilor afecta\u021bi. Calitatea vie\u021bii este influen\u021bat\u0103 considerabil de tratamentul prescris. (Acta Derm Venereol, 2015)
La nivel global, satisfac\u021bia pacien\u021bilor a devenit un element important \u00een alegerea tratamentului de c\u0103tre medicul curant, astfel \u00eenc\u00e2t orientarea c\u0103tre pacient nu mai este o teorie, ci o practic\u0103.
Un studiu care a urm\u0103rit satisfac\u021bia pacien\u021bilor (213 pacien\u0163i) cu ustekinumab \u00een tratamentul psoriazisului, pl\u0103ci moderate p\u00e2n\u0103 la severe, \u00een compara\u021bie cu terapia biologic\u0103 anterioar\u0103, evaluez\u0103 scorurile de satisfac\u021bie a tratamentului global, indicii de eficacitate \u0219i confort pentru ustekinumab. \u00cembun\u0103t\u0103\u021birea satisfac\u021biei dintre tratamentul anterior \u0219i ustekinumab a fost semnificativ\u0103 pentru fiecare dintre cei 3 indici (p <0,001). Nu au existat interac\u021biuni semnificative sau diferen\u021be de satisfac\u021bie \u00een timpul tratamentului.
Optimizarea satisfac\u021biei pacientului este esen\u021bial\u0103 pentru \u00eembun\u0103t\u0103\u021birea aderen\u0163ei \u0219i implicit a rezultatelor. Ustekinumab a fost clasat \u00een topul preferin\u0163elor, urmat de golimumab, infliximab \u0219i adalimumab. 93,5% dintre pacien\u0163i au considerat terapia ca fiind cea mai bun\u0103 terapie primit\u0103 vreodat\u0103. Acest aspect poate fi atribuit eficacit\u0103\u021bii ridicate, profilului favorabil risc-beneficiu \u0219i modului convenabil de administrare a terapiei biologice. (Raport Acta Derm Venereol, 2015)
Experien\u021ba clinic\u0103 real\u0103 cu ustekinumab la pacien\u021bii cu psoriazis moderat sau sever: o analiza multivariat\u0103 controlat\u0103 pentru v\u00e2rst\u0103, sex, severitatea bolii, durata bolii \u0219i num\u0103rul de terapii sistemice anterioare, confirm\u0103 o mai mare satisfac\u021bie cu terapii biologice comparativ cu terapia topic\u0103 local\u0103, fototerapia sau terapia sistemic\u0103 tradi\u021bional\u0103.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/novartis_logo_pos_rgb.jpg” align=”center” _builder_version=”3.19.18″ max_width=”30%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Cosentyx\u00ae – Tratamentul complet pentru boala psoriazic\u0103<\/span>
Speakeri: Prof. Dr. Daciana Elena Br\u0103ni\u0219teanu, Conf. Dr. C\u0103t\u0103lin Popescu<\/span><\/p>\n

Cosentyx\u00ae este un anticorp monoclonal, 100% uman, indicat pentru tratamentul psoriazisului \u00een pl\u0103ci, moderat p\u00e2n\u0103 la sever.
IL-17A este o citokin\u0103 esen\u021bial\u0103 \u00een psoriazis \u0219i \u00een psoriazisul artropatic. Cosentyx\u00ae \u021binte\u0219te \u00een mod direct IL-17A \u0219i o blocheaz\u0103, indiferent de sursa de provenien\u021b\u0103 a acesteia.
Cosentyx\u00ae asigur\u0103 tratamentul complet pentru diferite manifest\u0103ri ale psoriazisului (psoriazis cutanat, psoriazis artropatic, al scalpului, unghial \u0219i palmo-plantar).
Sub tratament cu Cosentyx\u00ae, 8 din 10 pacien\u021bi ating PASI 90 la s\u0103pt\u0103m\u00e2na 16, iar 4 din 10 pacien\u021bi ating PASI 100 la s\u0103pt\u0103m\u00e2na 16. Aproximativ 100% din ratele de r\u0103spuns PASI s-au men\u021binut la 5 ani.
R\u0103spunsuri importante se \u00eenregistreaz\u0103 la pacien\u021bii naivi, aproximativ 9 din 10 pacien\u021bi naivi ating\u00e2nd PASI 90 la s\u0103pt\u0103m\u00e2na 16.
Un r\u0103spuns important la reluarea tratamentului au ob\u021binut \u0219i pacien\u021bii care au \u00eentrerupt tratamentul, 94% dintre ace\u0219tia ating\u00e2nd PASI 75 la 12 s\u0103pt\u0103m\u00e2ni.
\u00cen ceea ce prive\u0219te pacien\u021bii cu psoriazis artropatic, trata\u021bi cu Cosentyx\u00ae, aproximativ 80% dintre ace\u0219tia nu au prezentat progresia leziunilor structurale la 3 ani.
Rezultate favorabile se \u00eenregistreaz\u0103 \u0219i pentru pacien\u021bii cu psoriazis palmo-plantar, aproximativ 40% dintre pacien\u021bi ob\u021bin\u00e2nd palme \u0219i t\u0103lpi curate sau aproape curate la s\u0103pt\u0103m\u00e2na 16. Evolu\u021bia favorabil\u0103 este men\u021binut\u0103 \u0219i chiar se \u00eembun\u0103\u021be\u0219te \u00een timp, astfel \u00eenc\u00e2t la 2,5 ani, aproximativ 60% dintre pacien\u021bi ob\u021bin palme \u0219i t\u0103lpi curate sau aproape curate.
Leziunile din psoriazisul unghial s-au ameliorat cu aproximativ 50% la s\u0103pt\u0103m\u00e2na 16, \u0219i au continuat s\u0103 se amelioreze odat\u0103 cu continuarea tratamentului, datele la 2,5 ani de tratament relev\u00e2nd o ameliorare a leziunilor unghiale cu peste 70% fa\u021b\u0103 de momentul ini\u021bial.
Aproximativ 60% dintre pacien\u021bii cu psoriazis al scalpului moderat p\u00e2n\u0103 la sever trata\u021bi cu Cosentyx\u00ae au atins PSSI 90 \u00een s\u0103pt\u0103m\u00e2na 24.
Tratamentul cu Cosentyx\u00ae a fost asociat cu o imunogenicitate de sub 1%, acest fapt contribuind la o tolerabilitate bun\u0103 \u0219i la rezultate semnificative clinic \u0219i sus\u021binute \u00een timp.
Cosentyx\u00ae este disponibil sub form\u0103 de stilou SensoReady\u00ae, pentru a face auto-injectarea c\u00e2t mai u\u0219oar\u0103 \u0219i mai confortabil\u0103 posibil. Cosentyx\u00ae 300 mg se administreaz\u0103 subcutanat, ini\u021bial s\u0103pt\u0103m\u00e2nal, timp de 5 s\u0103pt\u0103m\u00e2ni, apoi se continu\u0103 lunar cu doza de \u00eentre\u021binere.
Utilizat la peste 200.000 pacien\u021bi \u0219i f\u0103r\u0103 eviden\u021bierea de noi semnale privind siguran\u021ba de-a lungul a 5 ani, Cosentyx\u00ae asigur\u0103 tratamentul complet pentru boala psoriazic\u0103.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/LMB_H_4C.jpg” align=”center” disabled_on=”off|off|off” _builder_version=”3.19.18″ max_width=”18%”][\/et_pb_image][et_pb_text _builder_version=”3.19.18″]<\/p>\n

S\u0103 g\u00e2ndim dincolo de remisiunea clinic\u0103 \u00een psoriazis<\/span>
Speakers: Prof. Dr. Daciana Elena Br\u0103ni\u0219teanu, Dr. Carmen Curea<\/span><\/p>\n

\u00cen cazul psoriazisului \u00een pl\u0103ci moderat-sever, datele din literatur\u0103 demonstreaz\u0103 existen\u021ba unei poveri semnificative a bolii, ce are leg\u0103tur\u0103 at\u00e2t cu semnele \u0219i simptomele cutanate ale acestei afec\u021biuni, c\u00e2t \u0219i cu elemente emo\u021bionale, psiho-sociale \u0219i func\u021bionale corelate cu \u201dvizibilitatea\u201d specific\u0103 suferin\u021belor dermatologice \u0219i cu localizarea afect\u0103rii cutanate (scalp, unghii, palmo-plantar, genital).
Tot din literatur\u0103 \u0219tim c\u0103 remisiunea complet\u0103 sau aproape complet\u0103 a leziunilor psoriazice este \u00eenso\u021bit\u0103 de o ameliorare semnificativ\u0103 a calit\u0103\u021bii vie\u021bii pacien\u021bilor, iar scorul DLQI continu\u0103 s\u0103 se \u00eembun\u0103t\u0103\u021beasc\u0103 la niveluri de r\u0103spuns peste PASI 75. A\u0219adar atingerea unui astfel de status de \u201dpiele curat\u0103\u201d ridic\u0103 \u00een mare parte povara bolii acestor pacien\u021bi \u0219i are implica\u021bii evolutive favorabile pe toate planurile. Aceste considerente justific\u0103 setarea unor \u021binte terapeutice \u00eenalte \u00een controlul psoriazisului \u0219i totodat\u0103 alegerea unor terapii care \u0219i-au dovedit eficacitatea \u00een psoriazisul moderat-sever, inclusiv a celui localizat \u00een zone speciale, considerate dificil de tratat.
\u00cenainte de introducerea terapiilor biologice pentru psoriazis, atingerea unor \u021binte terapeutice ambi\u021bioase, de tipul remisiunii complete, era greu de sus\u021binut \u00een practica clinic\u0103. Ast\u0103zi \u00eens\u0103, mai multe produse biologice, din diferite clase terapeutice, pot induce un nivel de cur\u0103\u021bare a pielii complet sau aproape complet, iar evaluarea eficacit\u0103\u021bii acestora poate fi obiectivat\u0103 prin scoruri precum PASI, PSSI, NAPSI sau PPASI.
Inhibitorii IL-17A reprezint\u0103 o clas\u0103 terapeutic\u0103 relativ nou\u0103, ce ac\u021bioneaz\u0103 specific asupra reac\u021biilor fiziopatologice din psoriazis \u0219i ofer\u0103 un nivel de r\u0103spuns terapeutic \u00eenalt, rapid instalat \u0219i men\u021binut \u00een timp. \u00centre aceste produse, ixekizumab, at\u00e2t din studiile clinice proprii c\u00e2t \u0219i prin rezultatele din practica clinic\u0103 curent\u0103 (via\u021ba real\u0103), a demonstrat o eficacitate ridicat\u0103 pentru majoritatea pacien\u021bilor cu psoriazis \u00een pl\u0103ci moderat-sever, inclusiv cu afectare palmo-plantar\u0103, la nivelul scalpului, unghiilor sau genital.<\/p>\n

Let\u2019s think beyond clinical indicators of skin clearance<\/span>
Speakers: Prof. Daciana Elena Br\u0103ni\u0219teanu, Dr. Carmen Curea<\/span><\/p>\n

For moderate to severe psoriasis, scientific evidence show a significant burden of the disease, which is connected not only with the signs and symptoms of psoriasis, but also with emotional, psychosocial and functional elements that are corelated with the \u201dnoticeability\u201d specific to dermatological diseases and with the localisation in hard-to-treat areas (scalp, nails, palmo-plantar, genital).
Also, we know from medical literature that achieving complete\/almost complete skin clearance generates an increase in the QoL of the patients and DLQI score continues to improve beyond PASI 75. That is why, achieving a complete skin clearance status diminishes the burden of the disease for these patients and has favourable implications at all levels. These are reasons for setting elevated treatment goals and for choosing therapies that allow achieving complete skin clearance and improvement of hard-to-treat areas for patients with psoriasis.
Prior to biological therapies for psoriasis, achieving elevated treatment goals like PASI 90 or PASI 100 was difficult to achieve and sustain in daily clinical practice. Nowadays, there are different biological therapies, with distinct MoAs, that can induce a complete\/almost complete skin clearance and the evaluation of their efficacy can be measured by using scores like PASI, PSSI, PPASI or NAPSI.
IL-17A inhibitors represent a new therapeutical class which targets specifically the physiopatological responses of psoriasis and offers a high therapeutic efficacy, with a rapid onset of action and maintenance of response in time. Ixekizumab has demonstrated through it\u2019s clinical studies and from the results in daily clinical practice (real life results) that it can offer high efficacy for the majority of patients with moderate to severe psoriasis and inhibition on psoriasis in hard-to-treat areas.<\/p>\n

\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/logo_Solartium.eps_.jpg” align=”center” _builder_version=”3.19.18″ max_width=”27%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

NOUTATI IN TRATAMENTUL ACNEEI: <\/span>
\nLACTIFERON\u00ae DERMA, ALTERNATIVA EFICIENTA SI SIGURA LA PACIENTII CU ACNEE VULGARA SI ROZACEE\u201d <\/span>
\nSpeaker: Sanda Mirela Cherciu<\/span><\/p>\n

Acneea vulgara este o afectiune cronica, multifactoriala, cu o etiologie complexa si un impact psihologic important asupra calitatii vietii pacientilor. Studii recente au demonstrat ca administrarea orala a unui preparat pe baza de lactoferina, zinc si nicotinamida poate fi benefica la pacientii cu acnee vulgara sau rozacee, mai ales in asociere cu terapia topica. Lactoferina, o proteina multifunctionala din familia transferinelor, a demonstrat in numeroase studii clinice ca are importante proprietati antibacteriene, antiinflamatoare si imunomodulatoare. In cadrul a doua studii clinice administrarea a 1-2 tablete pe zi de lactoferina timp de 8 saptamani a redus semnificativ secretia de sebum si numarul total de leziuni inflamatorii si noninflamatorii. Recent s-a evaluat in cadrul unui studiu clinic randomizat eficienta si siguranta unui preparat care combina lactoferina si zincul la pacientii cu acnee usoara spre moderata. Administrarea orala timp de 3 luni a acestei combinatii a redus semnificativ leziunile inflamatorii si noninflamatorii, cat si secretia de sebum, combinatia fiind bine tolerata de toti pacientii. O alta substanta utilizata frecvent la pacientii cu acnee este nicotinamida, forma activa a vitaminei B3. Studii recente au demonstrat ca nicotinamida are un important efect antibacterian si antiinflamator, comparabil cu cel al antibioticelor, dar fara efecte adverse si risc de dezvoltare a rezistentei bacteriene. In tratamentul acneei, administrarea orala a unui preparat pe baza de nicotinamida, zinc si cupru a determinat o reducere semnificativa a numarului total de leziuni acneice dupa doar 4 saptamani de administrare.
\nIn cadrul simpozionului se va evalua eficienta si tolerabilitatea Lactiferon Derma, un nou preparat oral pe baza de lactoferina, zinc, nicotinamida si cupru la pacientii cu acnee vulgara si rozacee.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding=”27px|0px|27px|0px|false|false” _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/antibiotice_medium_slogan_white.jpg” align=”center” _builder_version=”3.19.18″ max_width=”20%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Compania Antibiotice \u2013 lider mondial \u00een produc\u0163ia de nistatin\u0103; expertiz\u0103 \u015fi recunoa\u015ftere \u00een dermatologie<\/span>
Speakeri: Daciana Br\u0103ni\u015fteanu, Monica H\u0103ncianu<\/span><\/p>\n

Compania Antibiotice este cel mai important produc\u0103tor rom\u00e2n de medicamente generice, av\u00e2nd sediul central \u00een Ia\u0219i, capitala istoric\u0103 a Rom\u00e2niei. Cu o tradi\u021bie de 63 de ani \u0219i un portofoliu ce ast\u0103zi dep\u0103\u0219este 150 de produse, compania \u0219i-a c\u00e2\u0219tigat renumele miz\u00e2nd pe performan\u021b\u0103 prin calitate. Echipa Antibiotice a reu\u0219it s\u0103 fac\u0103 medicamentele valoroase accesibile nu doar pe pia\u021ba din Rom\u00e2nia ci \u0219i \u00een alte 70 de \u021b\u0103ri ale lumii. Mai mult, substan\u021b\u0103 activ\u0103 nistatin\u0103, produs\u0103 pe platforma de la Ia\u0219i, plaseaz\u0103 compania ca lider \u00een topul mondial pe acest segment. Dincolo de recunoa\u0219terea c\u00e2\u0219tigat\u0103 la nivel global, brandul Antibiotice r\u0103m\u00e2ne ferm dedicat misiunii sale de a face rom\u00e2nilor s\u0103n\u0103tatea \u0219i via\u021ba mai bun\u0103. Portofoliului de antibiotice si medicamente topice esen\u0163iale \u00een tratamentul dermatologic, s-a al\u0103turat gama Nutriensa de suplimente alimentare con\u0163in\u00e2nd extracte standardizate din plante, vitamine \u015fi minerale, oferind astfel dermatologilor o palet\u0103 larg\u0103 de produse ce pot fi recomandate spre beneficiul pacien\u0163ilor.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=”on|on|on” _builder_version=”3.19.18″ disabled=”on”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/LEO_Logo.jpg” _builder_version=”3.19.18″ max_width=”15%” module_alignment=”center”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_margin=”-36px||” disabled_on=”on|on|on” _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600″ disabled=”on”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

MATRIOSKA<\/strong> – parteneriatul terapeutic,\u00a0\u00a0<\/span>dincolo de aparen\u021b\u0103<\/span><\/p>\n

MATRIOSKA – parteneriatul terapeutic, dincolo de aparen\u021b\u0103, este un workshop experien\u021bial, organizat de LEO Pharma \u00een cadrul Academiei LEO, \u0219i sus\u021binut de Dana Dumitru \u2013 psihoterapeut, coach \u0219i trainer.<\/p>\n

Acest atelier vine \u00een \u00eent\u00e2mpinarea unei realit\u0103\u021bi cu care ne confrunt\u0103m cu to\u021bii: modul \u00een care rela\u021bion\u0103m impacteaz\u0103 via\u021ba noastr\u0103 personal\u0103, rela\u021biile cu cei dragi, profesia, complianta pacien\u021bilor no\u0219tri, succesul \u0219i fericirea personal\u0103.<\/p>\n

Ce ne propunem \u00een acest atelier?<\/strong>
\u2022 S\u0103 aflam cum putem construi \u0219i mai bine un parteneriat cu pacientul, care s\u0103 ajute complianta \u0219i rezultatul terapeutic.
\u2022 S\u0103 cre\u0219tem capacitatea noastr\u0103 de a ne adapta situa\u021biilor dificile din via\u021ba profesional\u0103 \u0219i privat\u0103.<\/p>\n

Ce vom explora \u00eempreun\u0103?<\/strong>
\u2022 Vom vedea care sunt elementele cheie ale parteneriatului terapeutic al secolului 21. Vom descoperi unele aspecte psihologice de care merit\u0103 s\u0103 \u021binem cont atunci c\u00e2nd interac\u021bion\u0103m cu pacientul, pentru c\u0103 adesea ele impacteaz\u0103 rezultatul terapeutic.
\u2022 Vom \u00eembun\u0103t\u0103\u021bi capacitatea noastr\u0103 de a ne gestiona emo\u021biile \u00een situa\u021bii provocatoare, chiar \u00een cabinet, de exemplu atunci c\u00e2nd e nevoie s\u0103 fie comunicat un diagnostic sever \u0219i vom parcurge c\u00e2teva moduri prin care o putem face.
\u2022 Vom explora capacitatea noastr\u0103 de a comunica, mai ales \u00een absen\u021ba cuvintelor.
\u2022 Vom aprofunda ce \u00eenseamn\u0103 \u0219i cum se formeaz\u0103 \u00eencrederea \u00een dinamica rela\u021biilor cu cei din jur, implicit rela\u021bia medic pacient.
\u2022 Vom parcurge c\u00e2teva elemente cheie din psihologie, care fac diferen\u021ba atunci c\u00e2nd vine vorba despre rela\u021biile interumane.<\/p>\n

Prin ce v\u0103 ve\u021bi \u00eembog\u0103\u021bii \u00een urma acestui atelier?<\/strong>
Acest workshop va permite o \u00een\u021belegere mai bun\u0103 a felului \u00een care func\u021bioneaz\u0103 rela\u021biile noastre de zi cu zi, a secretelor unei comunic\u0103ri clare \u0219i umane \u0219i va conduce la o aten\u021bie sporit\u0103 asupra min\u021bii \u0219i a emo\u021biilor noastre.
Toate aceste aspecte ne ajut\u0103 s\u0103 tr\u0103im o via\u021b\u0103 mai armonioas\u0103, \u0219i mai plin\u0103 de sens, \u00een toate aspectele ei.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/Sandoz.jpg” align=”center” _builder_version=”3.19.18″ max_width=”36%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_margin=”19px||” _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″ custom_margin=”-53px||”]<\/p>\n

Cum tratez topic onicomicozele<\/span>
\n Speaker: Catalin Popescu<\/span><\/p>\n

Onicomicoza este una dintre cele mai frecvent \u00eent\u00e2lnite boli ale unghiilor. Este mai frecvent \u00eent\u00e2lnit\u0103 la unghiile picioarelor \u0219i este mai adesea produs\u0103 de dermatofi\u021bi dec\u00e2t de levuri.
\nDincolo de impactul estetic, onicomicoza poate fi o surs\u0103 de infec\u021bii micotice repetate ale pielii extremit\u0103\u021bilor sau o poart\u0103 de intrare pentru infec\u021bii cutanate bacteriene.
\nTratamentul topic al onicomicozelor este de durat\u0103 \u0219i rata sa de succes depinde de tipul afect\u0103rii unghiale \u0219i de gradul de penetrare al medicamentului prin keratina dur\u0103 a lamei unghiale.
\nExinailner este un topic frecvent utilizat, care trateaz\u0103 infec\u021bia fungic\u0103 indiferent de etiologie. Are o formul\u0103 care \u00eei permite s\u0103 penetreze lama unghial\u0103 \u00een profunzime, modific\u00e2nd pH-ul \u0219i bloc\u00e2nd astfel dezvoltarea fungilor.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_color_bottom=”#ff6600″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

A&DPharma<\/span><\/strong><\/h3>\n

[\/et_pb_text][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/logo-charte.jpg” _builder_version=”3.19.18″ max_width=”21%”][\/et_pb_image][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Melascreen \u2013 gama de \u00eengrijire \u00eempotriva foto-\u00eemb\u0103tr\u00e2nirii \u0219i a petelor pigmentare<\/span>
\nSpeaker:\u00a0Sanda Mirela\u00a0<\/span>Cherciu\u00a0<\/span><\/p>\n

Melanina, principalul pigment responsabil de colorarea pielii, p\u0103rului \u0219i a ochilor se g\u0103se\u0219te \u00een piele, \u00een propor\u021bii variabile, \u00een func\u021bie de fototipul cutanat. Cantitatea de melanin\u0103 cre\u0219te ca r\u0103spuns de protec\u021bie la ac\u021biunea nociv\u0103 a razelor UV.
\nHiperpigmentarea este foarte frecvent\u0103, afect\u00e2nd, \u00een peste 90% din cazuri, femeile.
\nFoto-\u00eemb\u0103tr\u00e2nirea, ca \u0219i \u00een cazul hiperpigment\u0103rii, afecteaz\u0103, \u00een special, femeile, reprezent\u00e2nd cel mai important factor extrinsec de \u00eemb\u0103tr\u00e2nire al pielii. Razele UV afecteaz\u0103 ADN-ul celular \u0219i genereaz\u0103 cantit\u0103\u021bi crescute de compu\u0219i oxidan\u021bi, care ini\u021biaz\u0103 modific\u0103rile histologice \u0219i clinice ale pielii.
\nLaboratoarele Dermatologice Ducray au creat gama Melascreen, ce con\u021bine produse dedicate \u00eengrijirii \u00eempotriva foto-\u00eemb\u0103tr\u00e2nirii, lentigo acnitic \u0219i a petelor pigmentare (melasm\u0103, cloasm\u0103).
\nGama Melascreen este format\u0103 din 8 produse, reprezent\u00e2nd un program complet de \u00eengrijire, ce:
\n\uf0b7PROTEJEAZ\u0102 \u00eempotriva foto-\u00eemb\u0103tr\u00e2nirii: produsele din gama Melascreen UV SPF50+
\noaceste produse previn efectele nocive ale razelor UV asupra pielii
\n\uf0b7\u00ceMBUN\u0102T\u0102\u021aE\u0218TE ASPECTUL NEPL\u0102CUT al petelor maronii localizate: Melascreen crem\u0103 depigmentant\u0103
\noajut\u0103 la reducerea petelor hiperpigmentare \u0219i ofer\u0103 luminozitate zonelor cu pigmentare localizat\u0103
\n\uf0b7UNIFORMIZEAZ\u0102 nuan\u021ba tenului: produsele din gama Melascreen Eclat
\nouniformizeaz\u0103 culoarea tenului, au ac\u021biune anti-oxidant\u0103 \u0219i hidrateaz\u0103
\n\uf0b7CORECTEAZ\u0102 petele maronii: Melascreen crem\u0103 de m\u00e2ini, Melascreeen Ser global \u0219i Melascreen crem\u0103 de noapte
\noac\u021bioneaz\u0103 \u00eempotriva foto-\u00eemb\u0103tr\u00e2nirii, hidrateaz\u0103
\nProdusele Melascreen con\u021bin ingrediente active depigmenta de referin\u021b\u0103 ( inclusiv acidul azelaic utilizat \u00een medicamente), dozate exact, pentru un grad crescut de eficacitate.
\nStudiile clinice sus\u021bin ac\u021biunea produselor Melascreen pe melasm\u0103 \u0219i lentigo.<\/p>\n

<\/span><\/p>\n

<\/span><\/p>\n

Melascreen \u2013 Prevention and treatment of hyperpigmentation and photo-aging<\/span><\/p>\n

Melanin, the main pigment responsible for coloring of the skin, hair and eyes is present into the skin, in various quantities, depending on the skin phototype. Melanin quantity is increasing as an protection answer to the harmful actions of UV rays.
\nHyperpigmentation is very common, affecting more than 90% of women,
\nPhoto-aging, as hyperpigmentation, affects women in particular, being the most important factor in the aging of the skin. UV rays affects cellular DNA and are generating increased amounts of oxidizing compounds that initiate histological and clinical changes of the skin,
\nDucray Dermatological Laboratories have created the Melascreen Range, which contains dedicated products to the care of photo-aging, acnetic lentigo and pigmentation spots (melasma, chloasma).
\nThe Melascreen range includes 8 products, representing a complete care program, which:
\n\uf0b7PROTECTS against photo-aging: Melascreen UV SPF50 +
\nothese products prevent the harmful effects of UV rays on the skin
\n\uf0b7IMPROVES THE UNPLEASANT ASPECT of localized brown spots: Melascreen depigmenting cream
\nohelps to reduce hyperpigmentation spots and provides brightness to localized pigmentation areas
\n\uf0b7UNIFORMS the skin: Melascreen Eclat products
\nouniformizes the color of the skin, has anti-oxidizing action and moisturizes
\n\uf0b7\u2022 CORRECTION of the browns: Melascreen Hand Cream, Melascreeen Global Serum and Melascreen Night Cream
\noit acts against photo-aging and moisturizes
\nMelascreen products contains active reference depigmentation ingredients (including azelaic acid used in medicines), precisely dosed, for increased efficacy.
\nClinical studies support the action of Melascreen products on melasma and lentigo.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/Logo_ETA_RO-2018_06_28-13_37_13-UTC-1.png” _builder_version=”3.19.18″ max_width=”14%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_margin=”-45px||” _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

EAU THERMALE AV\u00c8NE \u2013 NOUT\u0102\u021aI \u00ceN PROTEC\u021aIA SOLAR\u0102<\/span>
Speaker:\u00a0Daciana Branisteanu<\/span><\/p>\n

Soarele are un efect pozitiv asupra pielii, sintetizeaz\u0103 vitamina D \u0219i creeaz\u0103 o stare de bun\u0103-dispozitie. Soarele, de asemenea, poate avea ac\u021biune nociv\u0103 asupra organismului, de la efectele negative pe termen scurt, precum arsurile solare \u0219i insola\u021bia p\u00e2n\u0103 la cele pe termen lung, cauzate de expunerea prelungit\u0103 la soare, f\u0103r\u0103 utilizarea produselor cu factor de protec\u021bie, adaptate tipului de piele. Putem vorbi, astfel, de leziuni la nivelul ADN-ului, care pot provoca cancer de piele.
Foto-\u00eemb\u0103tr\u00e2nirea este o alt\u0103 consecin\u021b\u0103 a expunerii cronice la soare f\u0103r\u0103 fotoprotec\u021bie, razele UVA distrug\u00e2nd colagenul \u0219i fibrele de elastin\u0103, \u00een acest fel fiind afectat\u0103 structura pielii.<\/p>\n

Gama de protec\u021bie solar\u0103 de la Eau Thermale Av\u00e8ne vine \u00een \u00eentampinarea nevoilor pielii prin noi tehnologii:
\uf0fcTehnologia SWOPTM (prezent\u0103 \u00een produsele de protec\u021bie solar\u0103 pentru copii) \u2013 transformarea fazei uleioase \u00een faz\u0103 hidratant\u0103, \u00een timpul aplic\u0103rii. Rezultatul este aplicare u\u0219oar\u0103 \u0219i o protec\u021bie solar\u0103 mai ridicat\u0103
\uf0fcNude Skin (prezent\u0103 \u00een toate produsele de protec\u021bie solar\u0103) \u2013 asociere de 2 ingrediente active, ce asigur\u0103 absorb\u021bia at\u00e2t a transpira\u021biei, c\u00e2t \u0219i a sebumului
\u00cencep\u00e2nd cu 2019, \u00een gama de protec\u021bie solar\u0103 Eau Thermale Av\u00e8ne, exist\u0103 produse noi:
\uf0fcSport Fluid SPF50+, dedicat persoanelor ce practiv\u0103 activit\u0103\u021bi sportive, asigur\u0103 protec\u021bie solar\u0103 foarte ridicat\u0103, fiind foarte rezistent la ap\u0103 \u0219i transpira\u021bie
\uf0fcB-Protect SPF50+, conceput pentru protec\u021bia solar\u0103 \u00een mediul urban. Formula 3 \u00een 1 a acestui produs asigur\u0103 ac\u021biune anti-UV, anti-poluare, d\u00e2nd, \u00een acela\u021bi timp, luminozitate tenului.
\u00cen cadrul gamei de protec\u021bie solar\u0103 Eau Thermale Av\u00e8ne avem \u0219i dispozitivul medical clasa I Sunsimed, ce ofer\u0103 un spectru foarte larg de protec\u021bie UVA \u2013 UVB \u0219i asigur\u0103 eficacitate, siguran\u021b\u0103 \u0219i toleran\u021b\u0103 ridicat\u0103.
Aplicarea SunsiMed este un mijloc excelent de protec\u021bie a ADN-ulu \u00een cazul iradierii solare repetate. SUSNSIMED previne keratoza actinic\u0103, cancerul de piele (except\u00e2nd melanomul) \u0219i foto-\u00eemb\u0103tr\u00e2nirea.<\/p>\n

EAU THERMALE AV\u00c8NE \u2013 NOVELTIES IN SUN CARE PROTECTION<\/span>
Speaker: Daciana Branisteanu<\/span><\/p>\n

The sun brings benefits to the skin, it synthetizes Vitamin D and creates well-being. The sun can also have negative effects on the body not only on short term, like sun burns and insolation, but also on long term, being caused by the prolonged exposure to the sun, without using sun protection products, according to the skin type. Thus, we may add to the list DNA lesions, which can lead to skin cancer.
Photo-aging represents another effect of chronical sun exposure, without using sun protection products, the UVA rays distroy collagen and elastin fibers. The consequence is that the skin structure is affected.<\/p>\n

Eau Thermale Av\u00e8ne Sun care range comes to the aid of the skin need, with new technologies:
\uf0fcSWOPTM technology (present in the Sun care products dedicated to children) \u2013 represents the transformation of the oily phase to the emollient phase, during the application. The result is that we have an easy application and a higher sun care protection.
\uf0fcNude Skin (present in all the Sun care range) \u2013 represents the association of 2 active ingredients, ensuring the absorbtion of not only perspiration, but also of the sebum
Eau Thermale Av\u00e8ne Sun care range brings novelties in 2019:
\uf0fcSport Fluid SPF50+, dedicated to sports persons, ensuring very high sun protection, being, also, very resistant to water and perspiration
\uf0fcB-Protect SPF50+, especially developed for sun protection in urban areas. The 3 in 1 formula of this product had anti-UV, anti-pollution action, ensuring, at the same time, a radiant complexion
In the Eau Thermale Av\u00e8ne Sun care range, we also have a class I medical device – Sunsimed, which offers a very broad UVA \u2013 UVB protection spectrum, ensuring efficacy, safety and high degree of tolerance.
The usage of Sunsimed represents and excellent DNA protection mechanism, in case of repeated solar iradiation. SUSNSIMED prevents actinic keratosis, skin cancer (except melanoma) and photo-aging.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/BIODERMA-BD.jpg” align=”center” _builder_version=”3.19.18″ max_width=”26%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Photoderm \u2013 Impinge rutina ingrijirii solare la nivelul urmator.<\/span>
Protectie solara cu puternic efect antioxidant<\/span><\/p>\n

Imbatranirea pielii poate fi cauzata de mai multe procese: soarele (imbatranire fotoindusa), miscarile faciale naturale (imbatranire indusa de mimica), trecerea normala a timpului (imbatranire cronologica) si hormoni (imbatranire hormonala). De cele mai multe ori, acesti factori sunt combinati si isi sumeaza efectele. Imbatranirea fotoindusa apare pe zonele expuse mai des si mai intens la soare: fata, ceafa, dosul mainilor etc. Expunerea la razele solare este responsabila de aproximativ 90% din simptomele imbatranirii cutanate premature, de aceea nevoile pacientilor cu aceste simptome sunt din ce in ce mai intense. Expunerea la soare fiind unul dintre factorii ce determina imbatranirea pielii, acesti pacienti sunt deja constienti de importanta utilizarii unui produs de protectie solara, zilnic. Oricum, ei observa continuu o agravare a semnelor de imbatranire, atunci cand folosesc un produs de protectie clasic. Acesti pacienti vor sa mearga mai departe: intreba de o protectie mai puternica, insa care sa exercikte si actiune de corectie.
Se stie ca UVA si UVB sunt principalele responsabile de fotoimbatranire, insa nu sumt singurele. De aceea pacientii observa ca utilizarea unui produs de protectie solara, zilnic, nu este suficient.
In realitate, lumina vizibila si radiatiile infrarosii au, de asemenea, impact asupra pielii: acestea genereaza stres oxidativ, care degradeaza dermul, generand riduri si lipsa fermitatii, iar la suprafata pielii, petele solare.
Pentru a oferi solutia completa, expertiza in tratarea pielii a Laboratoarelor Bioderma a lansat un produs care merge mai departe decat un produs clasic de protectie solara. Inovatia noastra combina protectia foarte inalta cu un complex inteligent de ingrediente active ce aduc beneficii petelor solare si ridurilor, vizand fiecare semn al imbatranirii fotoinduse. De fapt, actiunea antioxidanta a acestui complex actioneaza impotriva stresului oxidativ generat de lumina vizibila si de infrarosii, si ofera un spectru larg de protectie.
Complexul nostru inteligent este format din 3 ingrediente active:
– VITAMINA C: in forma derivata stabila, care devine activa cand ajunge in contact cu pielea. Ea inhiba sinteza de melanina.
– VITAMINA E: cel mai puternic antioxidant lipofilic, care actioneaza impotriva leziunilor oxidative.
– CENTELLA ASIATICA: stimuleaza sinteza de colagen si previne degradarea acestuia.
Datorita complexului inteligent de ingrediente active, Photoderm Spot Age SPF 50+ este cel mai complet produs de pe piata potrivit pentru pacientii care cauta un produs de protectie solara care corecteaza si previne hiperpigmentarea si ridurile.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image align=”center” max_width=”66%” src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/Sigla-Galenica_Format-Nevectorial.jpg” _builder_version=”3.19.18″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Rupatadina \u2013 Siguran\u0163a Utiliz\u0103rii<\/span>
Speaker:\u00a0Prof. Univ. Dr. Alin Tatu<\/span><\/p>\n

Rupatadina este o entitate chimic\u0103 nou\u0103, ce prezint\u0103 un efect antihistaminic \u0219i efect anti PAF prin interac\u021biunea cu receptori specifici \u0219i nu prin antagonism fiziologic, cu un profil mai larg asupra propriet\u0103\u021bilor anti-inflamatorii (J. Mullol . Allergy 2008; 63 (Suppl 87): 5-28)
Antihistaminic de genera\u021bia a doua, antagonist selectiv, pe termen lung al histaminei, cu activitate periferic\u0103 la nivelul receptorilor H1, rupatadina dovede\u0219te \u0219i efectele clinice de blocare PAF (factor de agregare plachetar\u0103) \u2013 cu efect de peste 1000 ori mai puternic dec\u00e2t histamina \u00een cre\u0219terea permeabilit\u0103\u021bii vasculare, asociat cu hiperreactivitate bron\u0219ic\u0103, a c\u0103rui activare ini\u021biaz\u0103 faza vascular\u0103 a procesului inflamator acut, prin eliberarea numero\u0219ilor mediatori ce agraveaz\u0103 reac\u021bia alergic\u0103.
Rupatadina prezint\u0103 nivel maxim de eficien\u021b\u0103 – fiind cel mai puternic blocant selectiv H1, \u0219i cel mai puternic blocant PAF,dar \u0219i nivel maxim de siguran\u021b\u0103!
\u00centr-un studiu controlat cu placebo efectuat la pacien\u021bi cu urticarie idiopatic\u0103 cronic\u0103, rupatadina a fost eficace \u00een ameliorarea scorului mediu de prurit fa\u021b\u0103 de nivelul de referin\u021b\u0103, dup\u0103 o perioad\u0103 de 4 s\u0103pt\u0103m\u00e2ni de tratament (modificare fa\u0163\u0103 de nivelul de referin\u0163\u0103: rupatadin\u0103 57,5%, placebo 44,9%) \u015fi sc\u0103dere a num\u0103rului mediu de leziuni cutanate (54,3% fa\u0163\u0103 de 39,7%).
\u00cen studiu comparativ cu levocetirizina, rupatadina a demonstrat superioritatea, at\u00e2t \u00een reducerea scorului mediu al num\u0103rului de papule (rupatadina 19.3%, levocetizina 4.3%) \u0219i a dimensiunii acestora (19.10% rupatadina, 17.10% levocetirizina) c\u00e2t \u0219i \u00een reducerea scorului mediu de prurit (32.4% rupatadina, 26.8% levocetirizina), amelior\u00e2nd scorul simptomatologiei totale \u0219i \u00eembun\u0103t\u0103\u021bind calitatea vie\u021bii.<\/p>\n

<\/p>\n

Rupatadina, prezint\u0103 un profil de eficien\u021b\u0103 \u0219i toleran\u021b\u0103 \u0219i la pacien\u021bii cu simptomatologie marcat\u0103 de \u201cCold Urticaria\u201d dar \u0219i la pacien\u021bii cu alergie la \u00een\u0163ep\u0103tura de insecte.
Cele mai frecvente reac\u021bii adverse \u00een studiile clinice controlate au fost somnolen\u021ba (9,5%), cefalea (6,9%) \u0219i oboseala (3,2%). Majoritatea reac\u021biilor adverse observate \u00een studiile clinice au fost u\u0219oare p\u00e2n\u0103 la moderate ca severitate \u0219i, de obicei, nu au necesitat oprirea terapiei.
Siguran\u021ba la nivel cardiac a rupatadinei a fost evaluat\u0103 \u00eentr-un studiu QT\/QT aprofundat, prin urmare, nu ridic\u0103 probleme de siguran\u0163\u0103 la nivel cardiac.
Molecul\u0103 inovatoare, cu un mecanism complet \u0219i complex, rupatadina nu interfer\u0103 cu alimenta\u021bia, se poate asocia concomitent cu azitromicina, fluoxetina, lorazepam \u0219i alcool, f\u0103r\u0103 a demonstra efecte cognitive negative sau psihomotorii (inclusiv capacitatea de a conduce).<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image align=”center” max_width=”41%” src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/Logo-Sanofi-Genzyme.jpg” _builder_version=”3.19.18″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Dupilumab: Un nou standard \u00een tratamentul dermatitei atopice moderate \u015fi severe<\/span>
Speaker: Prof. Dr.\u00a0<\/span>Daciana Br\u0103ni\u015fteanu<\/span><\/p>\n

Dermatita Atopic\u0103 (DA) este o boal\u0103 grav\u0103 care afecteaz\u0103 at\u00e2t copiii c\u00e2t \u015fi adul\u0163ii. DA este o boal\u0103 inflamatorie cronic\u0103 sistemic\u0103 \u015fi nu doar o boal\u0103 de piele intermitent\u0103, a\u015fa cum era considerat\u0103 \u00een trecut. Pielea f\u0103r\u0103 leziuni (cu aspect normal) nu este \u00eens\u0103 piele indemna din cauza inflama\u0163iei subiacente persistente. IL4 \u015fi IL13, ca parte a mecanismului inflama\u0163iei de Tip2\/Th2, sunt citokine cheie \u00een fiziopatologia dermatitei atopice. Dupilumab este primul tratament pentru dermatita atopic\u0103 ce furnizeaz\u0103 un control continuu \u015fi sigur pe termen lung, ac\u0163ion\u00e2nd pe cele dou\u0103 citokine responsabile de inflama\u0163ia subiacent\u0103. Mecanismul de ac\u0163iune unic inhib\u0103 semnalizarea dubl\u0103 IL4 \u015fi IL13. Eficacitatea rapid\u0103 \u015fi su\u0163inut\u0103 pe termen lung, asupra semnelor \u015fi simptomelor, dimensiunea leziunilor, intensitatea \u015fi severitatea pruritului, asupra calit\u0103\u0163ii vie\u0163ii, inclusiv somnul, anxietate \u015fi depresia. Un profil robust de siguran\u0163\u0103 \u015fi tolerabilitate, cu o rat\u0103 total\u0103 a evenimentelor adverse comparabil\u0103 cu placebo \u015fi f\u0103r\u0103 teste de laborator pentru monitorizare.<\/p>\n

Dupilumab: A new standard in the treatment of moderate to severe atopic dermatitis<\/span>
Speaker: Prof. Dr.\u00a0<\/span>Daciana Br\u0103ni\u015fteanu<\/span><\/p>\n

Atopic Dermatitis (AD) is a serious disease affecting both children and adults. AD is a chronic systemic inflammatory disease and not only an intermittent skin disease as previously thought. Non-lesional (normal looking) skin is not normal skin due to a persistent underlying inflammation. IL 4 and IL13, as part of the Type 2\/Th2 pathway, are key cytokines in AD pathophysiology. Dupilumab is the first therapy in AD that provides continuous, long term and safe disease control by targeting 2 key cytokines of underlying inflammation. Unique mechanism of action that inhibits the dual signalling of IL4 and IL13. Consistent, rapid and sustained long-term efficacy on signs and symptoms, as seen on lesion extent and severity pruritus intensity, quality of life, including sleep, anxiety and depression. Strong safety and tolerability profile with an overall rate of adverse events comparable to placebo and no laboratory monitoring required.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/image004.png” align=”center” _builder_version=”3.19.18″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″ custom_margin=”-40px||”]<\/p>\n

BOALA VENOAS\u0102 CRONIC\u0102: DE LA ETIOPATOGENIE LA PREVENIREA COMPLICA\u021aIILOR<\/span>
Speaker: R.F. Popa<\/span><\/p>\n

Istoricul de tromboz\u0103 venoas\u0103 profund\u0103 cre\u0219te riscul de insuficien\u021b\u0103 venoas\u0103 cronic\u0103 de 25.7 ori. Tratamentul cu glicozaminoglicani, de exemplu Vessel Due F, considerat un precursor natural de glicocalix, un glicozaminoglican compozit 80% heparan-sulfat \u0219i 20% dermatan-sulfat poate reface \u0219i p\u0103stra integritatea glicocalixului endotelial. Vessel Due F prin reducerea inflama\u021biei vasculare, diminu\u0103 propriet\u0103\u021bile trombogenice ale plasmei \u0219i opre\u0219te progresia bolii. Pacien\u021bii trebuie men\u021binu\u021bi pe produsul biologic original, Vessel Due F ini\u021biat de medicul specialist c\u00e2t mai mult posibil, dac\u0103 r\u0103spund bine din punct de vedere al eficacit\u0103\u021bii \u0219i siguran\u021bei terapeutice. Fiind un produs biologic, are o ac\u021biune complex\u0103 at\u00e2t la nivel micro, c\u00e2t \u0219i macrovascular. \u00cen anul 2018, Forumul Venos European, Uniunea Interna\u021bional\u0103 de Angiologie, Uniunea Interna\u021bional\u0103 de Flebologie \u0219i Ghidul Na\u021bional de Boal\u0103 Venoas\u0103 Cronic\u0103 recomand\u0103 Vessel Due F \u00eencep\u00e2nd cu stadiile usoare ale bolii datorit\u0103 ac\u021biunii la nivelul endoteliului \u0219i efectelor pleiotrope. Are nivel de dovezi\u00a0cu grad \u00eenalt (A) pentru vindecarea complet\u0103 a ulcerelor\u00a0\u00een asociere cu compresia elastic\u0103. \u00cen preven\u021bie Vessel Due F are rol important \u00een sc\u0103derea riscului de recuren\u021b\u0103 a trombozei venoase profunde neprovocat\u0103. Implica\u021biile clinice ale rezultatelor studiului SURVET confirm\u0103 beneficiile tratamentului extins cu Vessel Due F la pacien\u021bii cu tromboz\u0103 venoas\u0103 profund\u0103 neprovocat\u0103 pentru reducerea riscului de recuren\u021b\u0103 \u0219i datorit\u0103 riscului sc\u0103zut de s\u00e2ngerare similar placebo.<\/p>\n

CHRONIC VENOUS DISEASE: FROM ETIOPATOGENIA TO PREVENT COMPLICATION<\/span>
Speaker: R.F. Popa<\/span><\/p>\n

The history of deep vein thrombosis increases the risk of chronic venous insufficiency by 25.7 times. Treatment with glycosaminoglycans, for example Vessel Due F, considered a natural precursor of glycocalix, 80% heparan sulphate glycosaminoglycan and 20% dermatan sulfate, can restore and maintain the integrity of endothelial glycocalix. Vessel Due F reduces vascular inflammation, decreases plasma thrombogenic properties and stops the progression of the disease. Patients should be kept on the original biological product, Vessel Due F initiated by the specialist as much as possible if they respond well in terms of therapeutic efficacy and safety. Being a biological product, it has a complex action at both micro and macrovascular level. In 2018, the European Venous Forum, the International Union of Angiology, the International Phlebology Union and the National Guide for Chronic Venous Disease recommend Vessel Due F starting with mild stage of the disease due to action in the endothelium and pleiotrops effects. Very important is the level of high-grade evidence (A) for complete healing of the ulcers in combination with elastic compression. In prevention, Vessel Due F plays an important role in reducing the risk of recurrence of unprovoked deep vein thrombosis. The clinical implications of the results of the SURVET study confirm the benefits of extended Vessel Due F treatment in patients with unprovoked deep vein thrombosis to reduce the risk of recurrence and the low risk of bleeding similar to placebo.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/Global_Mylan_BHBW_Tile_RGB_FC_100_3mmB_OL.png” align=”center” _builder_version=”3.19.18″ max_width=”27%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Elidel – o alternativ\u0103 terapeutic\u0103 sigur\u0103 \u0219i eficient\u0103 la CST pentru tratamentul dermatitei atopice<\/span>
Speaker: Petronela Cozma, C.M.I. Moara De Foc, Ia\u0219i, Rom\u00e2nia<\/span><\/p>\n

\u00cen tratamentul dermatitei atopice (DA), at\u00e2t corticosteroizii topici (CST) c\u00e2t \u0219i inhibitorii de calcineurin\u0103 (ICT) au un rol bine definit, cu recomandarea special\u0103 a ICT pentru tratamentul DA din zonele cu piele sensibil\u0103 \u0219i \u00een cazurile \u00een care pacien\u021bii nu au r\u0103spuns adecvat sau nu au tolerat CST, reduc\u00e2nd astfel riscul efectelor adverse cu ambele clase de medicamente. Pimecrolimus 1% crem\u0103 (Elidel\u00ae) este o op\u021biune terapeutic\u0103 important\u0103 \u00een tratamentul adul\u021bilor, adolescen\u021bilor \u0219i copiilor cu v\u00e2rsta mai mare de 2 ani, cu DA u\u0219oar\u0103 p\u00e2n\u0103 la moderat\u0103, fiind de prim\u0103 alegere \u00een special pentru zonele sensibile ale pielii. Pimecrolimus trateaz\u0103 eficient DA, poate fi utilizat \u00een tratamentul de scurt\u0103 durat\u0103 al semnelor \u015fi simptomelor eczemei atopice \u015fi intermitent \u00een tratamentul de lung\u0103 durat\u0103 pentru prevenirea progresiei c\u0103tre pusee acute. \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii pacien\u021bilor \u0219i, de asemenea, are un efect de reducere a nevoii de steroizi, beneficiu important pentru pacien\u021bii cu afec\u021biuni concomitente cum ar fi astmul bronsic \u0219i rinita alergic\u0103. Spre deosebire de CST, pimecrolimusul nu cauzeaz\u0103 disfunc\u021bia barierei epidermice sau atrofia pielii, nu se \u00eenso\u021be\u0219te de cre\u0219terea riscului de infec\u021bii ale pielii \u0219i, astfel, poate fi o terapie preferat\u0103 de c\u0103tre pacien\u021bi.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/04\/DERMEDIC-Recommended-by-dermatologists.png” align=”center” _builder_version=”3.19.18″ max_width=”40%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

Inova\u0163ie \u00een protec\u0163ia solar\u0103 \u2013 fotoprotec\u0163ie \u00eempotriva radia\u0163iilor infraro\u015fii \u015fi a luminii vizibile<\/span>
Autori: Dr. E. Trznadel-Grodzka, Dr. S. Grzegorzewska, Dr. K. Bazela<\/span>
Speaker: Dr. K. Bazela, Institutul de Dezvoltare \u1e63i Cercetare Biogened, Dermedic, Polonia<\/span><\/p>\n

Introducere: \u00cen ultimii ani a fost demonstrat c\u0103 radia\u1e6diile electromagnetice din spectrele de lumin\u0103 ultraviolet, vizibil\u0103 \u1e63i infraro\u1e63ie produc efecte biologice. Din aceast\u0103 cauz\u0103, protec\u1e6dia solar\u0103 sigur\u0103 \u1e63i eficace trebuie s\u0103 confere protec\u1e6die pentru tot spectrul luminii solare. Filtrele UV sunt deja bine cunoscute pentru protec\u1e6dia eficace \u00eempotriva efectelor adverse ale radia\u1e6diilor ultraviolete, \u00een timp ce antioxidan\u1e6dii sunt considera\u1e6di ca o modalitate suplimentar\u0103 de protec\u1e6die \u00eempotriva efectelor luminii vizibile \u1e63i a radia\u1e6diilor infraro\u1e63ii.
Materiale \u1e63i metode: Prezentarea con\u1e6dine teste de siguran\u1e6d\u0103 \u1e63i eficacitate pentru produse de protec\u1e6die solar\u0103 create \u00een concordan\u1e6d\u0103 cu acest concept de protec\u1e6die cu spectru larg.
Rezultate: Au fost create formule inovatoare bazate pe filtre UV \u1e63i substan\u1e6de active printre care se num\u0103r\u0103 antioxidan\u1e6dii. Studiile \u201din vitro\u201d demonstreaz\u0103 eficacitatea substan\u1e6delor active urm\u0103rind \u00een principal mecanismele de generare ale agresiunilor cauzate de expunerea la IR \u1e63i LV (ex. inhibarea produc\u1e6diei de citokine \u1e63i mediatori proinflamatori: IL-1\u03b1, IL-6, TNF\u03b1, PGE2, COX-2; stimularea activit\u0103\u1e6dii enzimelor cu rol antioxidant \u1e63i a biosintezei de colagen). \u00cen acest sens a fost demonstrat\u0103 eficacitatea protec\u1e6diei cu spectru larg. Factorii de protec\u1e6die UVA \u1e63i UVB au fost evalua\u1e6di \u00een conformitate cu standardele ISO.
Au fost studiate varia\u1e6diile de temperatur\u0103 la nivelul pielii, expus\u0103 la radia\u1e6dii IR, \u00eenainte \u1e63i dup\u0103 aplicarea produsului fotoprotector (s-a observat o sc\u0103dere medie de 0.8\uf0b0C \u00een cazul pielii protejate comparativ cu cea neprotejat\u0103). Toleran\u1e6da \u1e63i siguran\u1e6da produselor a fost confirmat\u0103 de c\u0103tre voluntarii participan\u1e6di \u00een cadrul studiului.
Concluzie: \u00cen cosmetologia modern\u0103 este necesar\u0103 o abordare \u1e63tiin\u1e6dific\u0103 pentru a crea produse de fotoprotec\u1e6die eficace. \u00cen continuare sunt necesare studii suplimentare \u1e63i metode standardizate pentru a oferi protec\u1e6dia pielii, \u00een special \u00een ceea ce prive\u1e63te efectele radia\u1e6diilor infraro\u1e63ii \u1e63i a luminii vizibile.<\/p>\n

\n

\n

Innovative sun care \u2013 infrared and visible light photoprotection<\/span>
Authors: E. Trznadel-Grodzka MD, PhD, S.Grzegorzewska PhD, K. Bazela PhD<\/span>
Speaker: K. Bazela PhD, Research and Development Institute Biogened, Dermedic, Poland<\/span><\/p>\n

Introduction: In the past few years it was demonstrated that electromagnetic radiation in the UV, visible and infrared ranges all produce biologic effects. For this reason, safe and effective sun care products should provide protection against exposure to the entire solar spectrum. Ultraviolet filters have been well established to be effective against the adverse effects of ultraviolet radiation, while antioxidants are believed to provide additional modalities for protection against the effects of visible light and infrared radiation.
Materials and methods: The presentation shows safety and efficacy tests of sun care products created according to the concept of broad-spectrum protection.
Results: In the first stage innovative formulas based on UV filters and additional active substances, including antioxidants have been created. In vitro studies proved the efficacy of actives on key pathways involved in the generation of damage caused by infrared and visible light exposure (e.g. inhibition of cytokines and inflammatory mediators production (IL-1\u03b1, IL-6, TNF\u03b1, PGE2, COX-2), stimulation of antioxidant enzymes activity and collagen biosynthesis). Then, the efficacy of broad-spectrum protection was demonstrated. UVB and UVA protection factors were evaluated in accordance with ISO methods. The effects of product application on the temperature of skin surface exposed to infrared radiation was studied (the average increase measured on cream protected skin was 0.8\uf0b0C lower than on unprotected skin). Finally, products safety and application properties were confirmed on the volunteers’ skin.
Conclusion: In modern cosmetology, a scientific approach is essential to create effective sun care products. Nevertheless, further studies and standardized methods are needed to provide consumers\u2019 protection, in particular with regard to visible light and infrared radiation.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/Ivatherm-logo.jpg” align=”center” _builder_version=”3.19.18″ max_width=”31%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding=”27px|0px|27px|0px|false|false” custom_margin=”-40px||” _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″]<\/p>\n

CICADERM Spray Regenerator cu Mimosa Tenuiflora – noua op\u021biune pentru vindecarea leziunilor cu pierdere de substan\u021b\u0103, pe suprafe\u021be mari sau \u00een arii greu accesibile<\/span>
Speaker: Daciana Br\u0103ni\u0219teanu<\/span><\/p>\n

CICADERM Spray absoarbe exudatul \u0219i vindec\u0103 rapid.
CICADERM Spray cu con\u021binut \u00eembog\u0103\u021bit \u00een Mimosa Tenuiflora, \u0219i care, prin ad\u0103ugarea de noi ingredien\u021bi activi precum \u0219i prin noul vehicul utilizat de tip flacon spray, l\u0103rge\u0219te aria de indica\u021bii la leziunile post-interven\u021bii dermatocosmetice extinse sau leziuni prin pierdere de substan\u021b\u0103, cu zone de macera\u021bie, din arii greu accesibile, unde cremele sunt dificil de aplicat.
Mimosa Tenuiflora este un ingredient natural, extras din \u201earborele pielii\u201d, cunoscut din practici str\u0103vechi. Introdus \u00een preparate dermatocosmetice, intervine \u00een toate cele 4 faze ale vindec\u0103rii av\u00e2nd un mecanism de ac\u021biune complex: produce hemostaza, reduce inflama\u021bia, stimuleaz\u0103 proliferarea celular\u0103, accelereaz\u0103 reconstructia pielii.
Mimosa Tenuiflora precum \u0219i adi\u021bia de activi noi, cu propriet\u0103\u021bi astringente, sicative \u0219i antiseptice (Smectita, Sulfatul de Cu si Zn) \u0219i Apa Termal\u0103 Herculane, cu efect anti-inflamator recunoscut, asigur\u0103 rezultate remarcabile produsului CICADERM Spray.
Studiul efectuat demonstreaz\u0103 o eficien\u021b\u0103 sporit\u0103 \u00een vindecarea accelerat\u0103, f\u0103r\u0103 riscuri de cicatrice, \u00een indica\u021biile vizate: leziunilor postexcizionale (electrocauterizare, electroexcizie), post-proceduri dermatocosmetice (peeling chimic, microneedling), precum \u0219i larga acceptabilitate cosmetic\u0103 relatat\u0103 de pacien\u021bii \u00eenrola\u021bi.<\/p>\n

\n

CICADERM Regenerator Spray with Mimosa Tenuiflora \u2013 a new option for healing of lesions with loss of substance on large surfaces or hardly accessible areas<\/span>
Speaker: Daciana Br\u0103ni\u0219teanu<\/span><\/p>\n

CICADERM Spray absorbs exudate and quickly heals the skin.
CICADERM Spray with enriched content in Mimosa Tenuiflora, and new active ingredients, as well as a new administration vehicle – bottle spray, enlarges the area of \u200b\u200bindications to extensive post dermatocosmetic procedures lesions or lesions with loss of substance, with maceration areas, in hard-to-reach areas where creams are difficult to be applied.
Mimosa Tenuiflora is a natural ingredient, extracted from the “skin tree”, known from ancient practices. Introduced in dermatocosmetic preparations, it intervenes in all four phases of wound healing with a complex mechanism of action: it produces haemostasis, reduces inflammation, stimulates cell proliferation, accelerates skin reconstruction.
S
Mimosa Tenuiflora as well as the addition of new active ingredients with astringent, siccative, and antiseptic properties (Smectite, Cu and Zn Sulfate) and Herculane Thermal Water, with proven anti-inflammatory effect, provide remarkable results for CICADERM Spray.
The study demonstrates an increased efficacy in accelerating healing, without risk of scar formation, in the following indications: post-excisional lesions (electrocautery, electroexcision), post dermatocosmetic procedures (chemical peeling, microneedling), as well as the wide cosmetic acceptability reported by the enrolled patients.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_image src=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/Logo-Isis-2.jpg” align=”center” _builder_version=”3.19.18″ max_width=”22%”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.18″ border_width_bottom=”3px” border_color_bottom=”#ff6600;”][et_pb_column type=”4_4″ _builder_version=”3.19.18″][et_pb_text _builder_version=”3.19.18″ border_color_bottom=”#ff9900″ custom_margin=”-40px||”]<\/p>\n

Hiperpigmentarea \u2013 o expertiz\u0103 unic\u0103 pentru rezultate f\u0103r\u0103 pete<\/span>
Speaker: Dana Andreea Molodoi<\/span><\/p>\n

Hiperpigmentarea este o afec\u0163iune dermatologic\u0103, un dezechilibru al procesului natural de pigmentare, const\u00e2nd \u00een acumularea excesiv\u0103 a melaninei rezultand cu apari\u0163ia petelor pigmentare. Hiperpigmentatiile afecteaz\u0103 90% dintre femei, majoritatea cu fototipurile III sau IV. Formele de manifestare pot fi diverse, \u00een func\u0163ie de factorii declan\u015fatori: melasma, lentigo actinic, lentigo senil, PIH. Noua expertiz\u0103 \u00een hiperpigmenta\u0163ii propune o alternativ\u0103 dermato-cosmetic\u0103 a moleculei de referin\u0163\u0103, baz\u00e2ndu-se pe trei mecanisme noi care afecteaz\u0103 procesul normal de pigmentare: pigmentarea palmo-plantar\u0103, vasculariza\u0163ie \u015fi lumin\u0103 albastr\u0103. Ultimele cercet\u0103ri despre cauzele complexe ce determin\u0103 apari\u0163ia hiperpigmentatiilor au condus la crearea unui complex activ sinergic patentat, DEPI-ACT COMPLEX, care ac\u0163ioneaz\u0103 \u00eenainte, \u00een timpul \u015fi dup\u0103 sinteza de melanin\u0103. DEPI-ACT asociaz\u0103 inhibitor de WNT, diacetyl boldin, extract pur de licorice \u015fi niacinamide cu ac\u0163iune sinergic\u0103 \u00een procesul de melanogenez\u0103. De asemenea, un rol major \u00een apari\u0163ia hiperpigmenta\u021biilor \u00eel are expunerea la radia\u0163iile ultraviolete \u015fi la lumin\u0103 albastr\u0103 care favorizeaz\u0103 stresul oxidativ \u015fi stimuleaz\u0103 sinteza de melanin\u0103. Noua abordare terapeutic\u0103 asociaz\u0103 filtrele UVA\/UVB cu melanina frac\u0163ionat\u0103, pentru a inhiba sinteza de melanin\u0103. Rezultatele excelente ale studiilor clinice au demonstrat c\u0103 asocierea ingredientelor active reprezint\u0103 o solu\u021bie inovativ\u0103 \u0219i eficient\u0103 \u00een tratamentul terapeutic al hiperpigmenta\u021biilor, av\u00e2nd de asemenea o toleran\u021b\u0103 optim\u0103 pentru toate tipurile de hiperpigmenta\u0163ii, pentru to\u0163i pacien\u0163ii (inclusiv femei \u00eens\u0103rcinate sau care al\u0103pteaz\u0103) \u015fi toate tipurile de piele, restabilind \u00een acela\u015fi timp homeostazia pielii.<\/p>\n

Hyperpigmentation \u2013 the unique expertise for a spotless result<\/span>
Speaker: Dana Andreea Molodoi<\/span><\/p>\n

Hyperpigmentation is a disorder of the natural process, leading to excessive accumulation of melanin at the surface of the skin, which is shown by the appearance of brown spots. Hyperpigmentation affects 90% of women, mostly with phototypes III or IV. The manifestations can vary depending on the trigger factors: melasma, actinic lentigo, senile lentigo, PIH. The new hyperpigmentation expertise proposes a dermatologically-cosmetic alternative to a reference molecule, based on three new mechanisms that affects the normal pigmentation process: palmo-plantar pigmentation, vascularization and blue light. Recent research on the complex causes of hyperpigmentation has led to the creation of a patented synergistically active complex, DEPI-ACT COMPLEX, which acts before, during and after melanin synthesis. DEPI-ACT associates WNT inhibitor, diacetyl boldin, pure licorice extract and niacinamide with synergistic action in the melanogenesis process. Likewise, a major role in the appearance of hyperpigmentation is the exposure to ultraviolet radiation and blue light that favors oxidative stress and stimulates melanin synthesis. The new therapeutic approach associates UVA \/ UVB filters with fractionated melanin to inhibit melanin synthesis. The excellent clinical results have demonstrated that the association of active ingredients is an innovative and effective solution in the therapeutic treatment of hyperpigmentation, also having optimal tolerance for all types of hyperpigmentation, for all patients (including pregnant women or breast-feeding) and at the same time recover the skin homeostasis.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop”][et_pb_row custom_padding=”61px|0px|69px|0px|false|false” _builder_version=”3.18.9″][et_pb_column type=”3_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_font_size_last_edited=”on|desktop” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark”]<\/p>\n

Contacteaz\u0103 operatorul PDI 2019<\/p>\n

[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n

Operatorul PDI 2019<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”3.19.4″ text_font=”||||||||”]\"\"<\/span><\/p>\n

<\/span><\/p>\n

<\/span><\/p>\n

Adresa: Str. A. Panu nr. 13, Iasi<\/span>
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Dac\u0103 firma pe care o reprezenta\u0163i dore\u015fte s\u0103-\u015fi promoveze produsele \u015fi serviciile \u00een cadrul PDI 2019, at\u00e2t \u00een timpul evenimentului, c\u00e2t \u015fi \u00een toat\u0103 perioada de organizare premerg\u0103toare acestuia, v\u0103 rug\u0103m s\u0103 ne contacta\u0163i. At\u00e2t organizatorii, c\u00e2t \u015fi operatorul evenimentului, Eventer.Net, v\u0103 stau la dispozi\u0163ie pentru orice informa\u0163ii \u00een plus sau clarific\u0103ri ve\u0163i avea nevoie. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-138","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=138"}],"version-history":[{"count":39,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/138\/revisions"}],"predecessor-version":[{"id":5648,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/138\/revisions\/5648"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}